Moreira Alvaro, Kahlenberg Samuel, Hornsby Peter
Department of PediatricsUniversity of Texas Health Science Center-San Antonio, San Antonio, Texas, USA
Department of PediatricsUniversity of Texas Health Science Center-San Antonio, San Antonio, Texas, USA.
J Mol Endocrinol. 2017 Oct;59(3):R109-R120. doi: 10.1530/JME-17-0117. Epub 2017 Jul 24.
Mesenchymal stem cells (MSCs) are self-renewing multipotent cells that have the capacity to secrete multiple biologic factors that can restore and repair injured tissues. Preclinical and clinical evidence have substantiated the therapeutic benefit of MSCs in various medical conditions. Currently, MSCs are the most commonly used cell-based therapy in clinical trials because of their regenerative effects, ease of isolation and low immunogenicity. Experimental and clinical studies have provided promising results using MSCs to treat diabetes. This review will summarize the role of MSCs on tissue repair, provide emerging strategies to improve MSC function and describe how these processes translate to clinical treatments for diabetes.
间充质干细胞(MSCs)是自我更新的多能细胞,具有分泌多种生物因子的能力,这些生物因子可恢复和修复受损组织。临床前和临床证据证实了MSCs在各种医学病症中的治疗益处。目前,由于其再生作用、易于分离和低免疫原性,MSCs是临床试验中最常用的基于细胞的治疗方法。实验和临床研究使用MSCs治疗糖尿病已取得了有前景的结果。本综述将总结MSCs在组织修复中的作用,提供改善MSCs功能的新策略,并描述这些过程如何转化为糖尿病的临床治疗。